Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (TARS) is a commercial-stage biopharmaceutical leader pioneering novel therapies for underserved ophthalmic conditions. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical developments, and strategic initiatives driving innovation in eye care therapeutics.
Access authoritative updates on XDEMVY commercialization progress, pipeline advancements for TP-04 and TP-05, and financial performance metrics. Our curated collection includes earnings reports, FDA correspondence, peer-reviewed research publications, and partnership announcements – all essential for understanding TARS's market position.
Key updates cover:
• Prescription drug approval statuses
• Clinical trial phase completions
• Commercialization partnerships
• Quarterly financial disclosures
Bookmark this page for unfiltered access to Tarsus Pharmaceuticals' official communications. For comprehensive analysis of how these developments impact the biopharmaceutical landscape, consult your financial advisor and review SEC filings.
Tarsus Pharmaceuticals (NASDAQ: TARS) has launched a new direct-to-consumer TV campaign for XDEMVY®, the first and only FDA-approved treatment for Demodex blepharitis. The campaign, titled "Your Mitey Problem," creatively showcases the root cause of the disease through a representation of mites on patients' eyelids.
Demodex blepharitis affects approximately 25 million people in the U.S., or 1 in 12 adults. It occurs when Demodex mites overpopulate on the eyelids, causing symptoms like redness, itching, and inflammation. The campaign aims to educate patients about the disease and encourage them to consult eye care providers about XDEMVY.
The multi-channel campaign is live on connected TV devices and streaming channels, with plans to include digital and social media components. Tarsus expects this innovative approach to reach a greater number of patients in need and drive action among providers and patients.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in the UBS Virtual Ophthalmology Day 2024. Aziz Mottiwala, Chief Commercial Officer, will engage in a virtual fireside chat on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET.
Tarsus, a company focused on addressing unmet needs in eye care through proven science and new technology, will provide a live webcast of the presentation. Interested parties can access the webcast and additional information through the events section of the Tarsus website. A replay of the presentation will be available on the company's website within 48 hours and will be archived for a time.
This participation underscores Tarsus's commitment to revolutionizing treatment for patients, particularly in the field of ophthalmology.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in the 2024 Wells Fargo Securities Healthcare Conference in Boston, MA. The company's CEO and Chairman, Bobby Azamian, M.D., Ph.D., along with CFO and Chief Strategy Officer Jeff Farrow, will engage in an in-person fireside chat on Wednesday, September 4, at 11:15 a.m. PT / 2:15 p.m. ET.
Tarsus, focused on addressing unmet needs in healthcare, particularly in eye care, will provide a live webcast of the presentation. Interested parties can access the webcast and additional information through the events section of the Tarsus website. A replay will be available within 48 hours and archived for a time.
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1. Year-to-date sales totaled $65.5 million. The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%. Tarsus expanded payer coverage, including Medicare, and is on track to deploy additional sales representatives by Q3 end. Despite the sales growth, Tarsus reported a net loss of $33.3 million for Q2. The company's cash position remains strong at $323.6 million as of June 30, 2024.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced it will host a live webcast on Thursday, August 8, 2024, at 1:30 p.m. PT / 4:30 p.m. ET to report its second quarter 2024 financial results and provide a corporate update. The company, focused on addressing unmet needs in eye care through proven science and new technology, will make the webcast accessible to participants via a provided link. A recorded version of the call will be available on the website shortly after the webcast concludes and will remain archived for approximately 90 days.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced its participation in three upcoming investor conferences. Executives will join fireside chats at the William Blair Growth Stock Conference on June 4, 2024, the Jefferies Global Healthcare Conference on June 5, 2024, and the Goldman Sachs Global Healthcare Conference on June 10, 2024. Attendees include Jeff Farrow, Chief Financial and Chief Strategy Officer, Aziz Mottiwala, Chief Commercial Officer, and Bobak Azamian, CEO and Chairman. Live webcasts will be accessible on Tarsus's website, with replays available within 48 hours.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that Bobak Azamian, M.D., Ph.D., CEO and Chairman, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference. The event aims to revolutionize treatment for patients, starting with eye care. The webcast and presentation details are available on the Tarsus website.
Tarsus Pharmaceuticals, Inc. reported a successful first quarter of 2024, with $24.7 million in net product sales of XDEMVY, an 89% increase over the previous quarter. The company delivered approximately 26,000 bottles of XDEMVY to patients, expanded its sales force, secured multiple commercial payer contracts, and strengthened its financial position with a public equity offering and financing commitment. Tarsus remains on-track for broad commercial coverage by the end of 2024 and Medicare coverage in 2025. The company continues to advance its pipeline and engage with the FDA on new treatments. Despite positive revenue growth, Tarsus saw an increase in net loss due to higher expenses, primarily in research and development as well as selling, general, and administrative costs.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will report its first quarter 2024 financial results on May 8, 2024. The company focuses on unmet needs in eye care. A live webcast will be held to provide the results and a corporate update.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
